GlassScriptPhysician profile
Melissa D Davis
NPI 1649499583
$1,434.71
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $172 · 2021: $225 · 2022: $107 · 2023: $343 · 2024: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.74 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $221.48 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $193.75 | 2020-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $151.96 | 2020-2021 | |
| Incyte Corporation | $135.74 | 2024 | Opzelura |
| Neos Therapeutics, LP | $135.24 | 2019-2024 | Cotempla Xr-Odt |
| Merck Sharp & Dohme LLC | $108.38 | 2020-2024 | Rotateq, Gardasil 9, Vaxelis |
| Supernus Pharmaceuticals, INC. | $70.09 | 2023-2024 | Qelbree, Qelbree |
| Shire North American Group INC | $64.01 | 2019 | |
| Glaxosmithkline, LLC. | $62.61 | 2019-2024 | Bexsero, Pediarix, Flulaval Quadrivalent |
| Vertical Pharmaceuticals, LLC | $62.32 | 2019-2024 | Relexxii |
| Lilly USA, LLC | $58.38 | 2022 | |
| Sanofi Pasteur INC. | $44.63 | 2021-2023 | |
| Cranial Technologies, INC | $35.08 | 2020-2021 | |
| Avion Pharmaceuticals | $29.53 | 2023 | Methylphenidate Hydrochloride |
| Ultragenyx Pharmaceutical INC. | $26.65 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $18.87 | 2023 | |
| Astellas Pharma US INC | $15.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.